67376-72-1

Usage

Uses

Used in Pharmaceutical Research and Development:
(2R,3S)-(-)-3,4-DIMETHYL-5,7-DIOXO-2-PHENYLPERHYDRO-1,4-OXAZEPINE is employed as a potential drug candidate in pharmaceutical research and development due to its pharmacological properties. Its unique molecular structure and stereochemistry make it a valuable compound for exploring new therapeutic avenues and developing innovative treatments for various medical conditions. Further studies are necessary to fully understand its potential applications and to optimize its use in the pharmaceutical industry.

InChI:InChI=1/C13H15NO3/c1-9-13(10-6-4-3-5-7-10)17-12(16)8-11(15)14(9)2/h3-7,9,13H,8H2,1-2H3/t9-,13-/m0/s1

Upstream product

• 299-42-3 ephedrine 
• 108-59-8 malonic acid dimethyl ester 
• 16695-14-0 Malonic acid monomethyl ester 

Downstream Products

• 98720-17-3 C₂₅H₂₇NO₄ 
• 1237025-10-3 (2R,3S,Z)-6-(4-(3-bromobenzyloxy)benzylidene)-3,4-dimethyl-2-phenyl-1,4-oxazepane-5,7-dione 
• 128735-68-2 (4R,5S)-5-((2R,3S,6S)-3,4-Dimethyl-5,7-dioxo-2-phenyl-[1,4]oxazepan-6-yl)-4-ethyl-2-methoxy-3-oxo-cyclopent-1-enecarboxylic acid methyl ester 
• 98720-19-5 C₂₅H₂₆BrNO₄ 
• 738628-08-5 (2R,3S)-6-((S)-1-tert-Butyl-5-phenyl-pent-2-ynyl)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 738628-05-2 (2R,3S)-6-((R)-1-Isopropyl-5-phenyl-pent-2-ynyl)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 69798-28-3 (E)-(2R,3S)-6-isobutylidene-3,4-dimethyl-2-phenylperhydro-1,4-oxazepine-5,7-dione 
• 123356-39-8 (2S,3S)-(Z)-isobutylidene-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 75291-15-5 (2S,3S)-(E)-butylidene-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 738627-95-7 (2S,3S)-(E)-(2,2-dimethylpropylidene)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 738628-02-9 (2S,3S)-(Z)-(2,2-dimethylpropylidene)-3,4-dimethyl-2-phenyl-[1,4]oxazepane-5,7-dione 
• 161297-28-5 (2R,3S)-(-)-6-Diazo-3,4-dimethyl-2-phenyl-1,4-oxazepan-5,7-dion 
• 65092-79-7 (2R)-6-(Z)-benzylidene-3c,4-dimethyl-2r-phenyl-[1,4]oxazepane-5,7-dione 
• 65092-79-7 (2R,3S)-3,4-Dimethyl-2-phenyl-6-[1-phenyl-meth-(E)-ylidene]-[1,4]oxazepane-5,7-dione 

Relevant academic research and scientific papers

Asymmetric syntheses of a GPR40 receptor agonist via diastereoselective and enantioselective conjugate alkynylation

Two asymmetric methods to synthesize a potent GPR40 receptor agonist are reported. Both synthetic routes utilize readily available, inexpensive starting materials and reagents. The first route relies on a highly diastereoselective conjugate alkynylation of an ephedrine-derived oxazepanedione acceptor. The second route features the enantioselective alkynylation of a Meldrum's acid-derived acceptor mediated by a chiral zinc cinchonidine reagent.

A SHORT EFFECTIVE PREPARATION OF CHIRAL N,3-DIMETHYL-5,7-DIOXO-2-PHENYLHEXAHYDRO-1,4-OXAZEPINES

An improved two-stage procedure has been devised for the synthesis in 50percent yield of the title compounds from ephedrine or pseudoephedrine enantiomers and dimethyl malonate using cyanuric chloride/pyridine to lactonise the intermediate ε-hydroxyacids.